# Clinical Trials Data BRAF - Document 10

# Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate

## Clinical Trial: https://clinicaltrials.gov/study/NCT01124669

"eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n\* Diagnosis of refractory non-small cell lung cancer\n\* Received sorafenib tosylate on protocol ECOG-E2501\n\* Available blood specimens\n\nPATIENT CHARACTERISTICS:\n\n\* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n\* See Disease Characteristics",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Samples submitted for research from patients enrolled on E2501",

Question:  
Based on the following clinical trial information, would a patient with a BRAF gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, having a BRAF gene mutation is not specifically mentioned as a requirement or exclusion. The main requirements are:  
  
- Diagnosis of refractory non-small cell lung cancer.  
- Receipt of sorafenib tosylate on protocol ECOG-E2501.  
- Availability of blood specimens.  
  
If the patient with a BRAF gene mutation meets these criteria (particularly having participated in protocol ECOG-E2501, which involved treatment with sorafenib tosylate), they could be eligible for the clinical trial. The BRAF mutation status does not seem to affect eligibility based on the given information. However, it's always advisable to confirm with the trial coordinators or review the full trial protocol for any additional, unlisted criteria.